WO2011049346A2 - Compositions for improving migration potential of stem cells - Google Patents

Abstract

The present invention relates to a composition for improving the migration potential of a stem cell, a method for evaluating the migration potential of a stem cell and a method for screening an adjuvant of cell therapy improving the migration potential of a stem cell. The present invention may be effectively used for enhancing the efficacy of neurological disease-treatment by inducing therapeutic stem cells to migrate efficiently to the lesion site.

Description

COMPOSITIONS FOR IMPROVING MIGRATION POTENTIAL

OF STEM CELLS

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

The present invention relates to compositions for improving migration potential of stem cells BACKGROUND OF TECHNIQUE

Adult stem cells derived from different types of tissues have different differentiation capacities and functional properties which may make them more or less effective for treating individual disorders (1). Clarification of these properties for each stem cell origin is necessary for the creation of clinical guidelines to aid in the selection of the optimal stem cell origin for patient treatment.

Mesenchymal stromal cells (MSCs) can improve the recovery of cerebral ischemia either by neuronal differentiation and replacement of damaged, or by providing neuroprotection to damaged neurons after migrating to the lesion site. The key factors governing the migratory capacity of stem cells, however, are largely unknown. Autologous MSCs are generally preferred for therapeutic transplantation because they are not subject to immune rejection. However, if the differentiation or migratory capacities of autologous MSCs lacks or are compromised, a universal donor approach should be adopted as an alternative. Therefore, it had been an important subject to identify the factors involved in stem cell migration.

Throughout this application, various publications and patents are referred and citations are provided in parentheses. The disclosures of these publications and patents in their entities are hereby incorporated by references into this application in order to fully describe this invention and the state of the art to which this invention pertains.

SUMMARY OF THE INVENTION

The present inventors have made intensive studies to elevate the efficacy of stem cell therapy by improving the migration potential of implanted stem cells to the lesion site. As results, we have discovered the factor involved in migration of the stem cells.

Accordingly, it is an object of this invention to provide a composition for improving the migration potential of a stem cell.

It is another object of this invention to provide a stem cell transformed with the composition of the present invention.

It is still another object of this invention to provide a composition for treating neurological diseases comprising the stem cell of the present invention.

It is further object of this invention to provide a method for evaluating the migration potential of a stem cell.

It is still further object of this invention to provide a method for screening an adjuvant of cell therapy improving the migration potential of a stem cell to treat neurological diseases. Other objects and advantages of the present invention will become apparent from the following detailed description together with the appended claims and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 represents the migratory capacity of MSCs depends on their origin. Fig. la shows the migratory activity of Ferumoxides-labeled mesenchymal stromal cells (MSCs) from various origins, including amyotrophic lateral sclerosis patient-derived MSC (ALSMSC), C-MSC (purchased from Cambrex), human umbilical cord-derived MSC (hUC-MSC), and umbilical cord blood-derived MSC (UCB-MSC) in the ischemic stroke model of rat brain by in vivo MR imaging. MR imaging shows that C-MSC, hUC-MSC, and UCB-MSC, which were implanted into the contralateral sides of ischemia damaged brains, migrated to the lesion site, but ALS-MSCs did not. Fig lb shows that the ALS-MSC did not migrate 35 days after implantation. Fig lc shows the result of in vitro cell migration assays indicating that C-MSC, hUC-MSC, and UCB- MSC had migratory capacity, but ALS-MSCs did not.

Fig. 2 represents expression levels of β-ΡΙΧ and migration-associated factors in MSCs from different origins. β-ΡΙΧ and some migration-associated gene expression levels were lower in ALS-MSC than C-MSC as assessed by quantitative PCR array (Fig. 2a). Expression levels of mRNA (Fig. 2b) and protein (Fig. 2c and 2d) were lowest in ALS-MSC.

Fig. 3 represents that the alteration of β-ΡΙΧ expression affects migratory capacity. Knockdown of β-ΡΙΧ mRNA and protein was induced in C-MSC with shRNA (Fig. 3a). β-ΡΙΧ over-expression in ALS-MSC with /3-P/X-Lentivirus increased ALS-MSC migratory capacity (Fig. 3b and 3c). β-ΡΙΧ knockdown decreased C-MSC migratory capacity (Fig. 3c).

Fig. 4 shows that In vivo migratory capacity of MSCs depends upon expression levels of β-ΡΙΧ. The migration of human MSCs to lesion sites in the rat stroke model was assessed with MR imaging. β-ΡΙΧ depleted C-MSCs did not migrate to lesion sites, while mock treated C-MSC did (Fig. 4a). β-ΡΙΧ over- expression restored the ability of ALS-MSCs to migrate to lesion sites (Fig. 4b).

Fig. 5 represents the confirmation of migration of implanted MSCs with MR imaging and immunohistochemistry. Considering the results of the MPGR image and the immunohistochemical staining, migration of MSCs to the contralateral lesion site from the primary injection site is found as migratory spots in the MPGR image

Fig. 6 represents the alteration of behavioral functions after the implantation of MSCs depending on their origin. A decrease in the neurologic deficit score (NDS) indicates an improvement in behavioral functions. As shown in this figure, there was no difference between the five groups prior to implantation, but the NDS was significantly lower in the C-MSC, hUC-MSC, and UCB-MSC groups (N=10 in each group) than in the ALS-MSC group (N=10) from 7 days after implantation although statistically significant difference was shown from 21 days after implantation. In other words, C-MSCs, hUC-MSCs, and UCB-MSCs significantly improved behavioral functions of ischemic stroke rats but ALS-MSCs did not. [*p<0.05 when compared with the PBS group, Wilcoxon Scores (Rank Sums) Test after Kruskal-Wallis Test].

Fig. 7 represents the result of quantitative PCR assay to evaluate the difference of migration associated genes between ALS-MSCs and C-MSCs

Fig. 8 represents the result of the evaluation of surface marker expression of ALS-MSCs, UCB-MSCs, hUC-MSCs, and C-MSCs. The cells were characterized by staining with the following anti-human antibodies: CD45-phycoerythrin (PE), CD44- fluorescein isothiocyanate (FITC) (DakoCytomation, Denmark), CD73-PE (BD Pharmingen, CA, USA), CD34-PE, CD29-F1TC, CD49C-PE, CD54-FITC, CD105-F1TC, CD106-FITC, HLA-DR-FITC, and PE- and FITC-conjugated isotype controls (Serotec, UK). After staining, cells were analyzed using flow cytometry (Calibur, CA, USA).l On flow cytometric analysis of surface marker expression, ALS-MSCs, UCB-MSCs, hUC- MSCs, and C-MSCs commonly demonstrate a CD45-CD34- CD29+CD73+CD105+CD44+HLA-DR- phenotype. These surface markers are not different in β-ΡΙΧ knockdowned C-MSCs and ^ZVoverexpressed ALS-MSCs.

Fig. 9 represents the comparison of behavioral functions between β-ΡΙΧ knockdowned and vehicle C-MSCs. The neurologic examination was performed daily as above described after the implantation of β-ΡΙΧ knockdowned and vehicle C- MSCs. As shown in this figure, there was no improvement in behavioral functions of the ischemic stroke rats (N=10) implanted with β-PD knockdowned C-MSCs when compared with the rats (N=10) implanted with vehicle C-MSCs. In other words, β- PIX knockdowned C-MSCs did not improve behavioral functions of ischemic stroke rats but vehicle C-MSCs did. [*p<0.05 when compared with the PBS group, Wilcoxon Scores (Rank Sums)].

Fig. 10 represents comparison of neurotrophic factors. When compared with C-MSCs, concentrations of SDF-Ια (A) and VEGF (B) were significantly decreased in culture supernatant of ALS-MSCs but concentration of BDNF (C) was not. The level of these neurotrophic factors is not affected by genetic modulation of β-ΡΙΧ.

Fig. 11 shows the vector map of pLenti6/V5-D-TOPO used in cloning β-PJX.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect of this invention, there is provided a composition for improving the migration potential of a stem cell, which comprises as an active ingredient a gene delivery system comprising a nucleotide encoding β-ΡΙΧ having the amino acid sequence of SEQ ID NO:2.

In another aspect of this invention, there is provided a method for improving the migration potential of a stem cell, comprising contacting to the stem cell a gene delivery system comprising a nucleotide sequence encoding β-ΡΙΧ having the amino acid sequence of SEQ ID NO:2.

The present inventors have made intensive studies to elevate the efficacy of stem cell therapy by improving the migration potential of implanted stem cells to the lesion site. As results, we have discovered that β-ΡΙΧ is a crucial factor involved in migration of stem cells.

The term "gene delivery system" as used herein, refers to any forms of carriers that harbor and transport exogenous nucleic acid molecules to a target cell or tissue. As used herein, "delivery" is used interchangeably with "transduction". At the level of tissue, the term "delivery" is used interchangeably with "spread". Therefore, the term "gene delivery system" may also be written as "gene transduction system" or "gene spread system".

The gene delivery system of this invention comprises any of gene delivery system used in gene therapy by those skilled in the art, preferably, plasmid, adenovirus (Lockett U, et al., Clin. Cancer Res., 3:2075-2080(1997)), adeno- associated virus (AAV, Lashford LS., et al., Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), retrovirus (Gunzburg WH, et al., Retroviral vectors. Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), lentivirus (Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999)), herpes simplex virus (Chamber R., et al., Proc. Natl. Acad. Sci USA, 92: 1411-1415(1995)), vaccinia virus (Puhlmann M. et al., Human Gene Therapy, 10:649-657(1999)) liposome ((Methods in Molecular Biology, Vol 199, S.C. Basu and M. Basu (Eds.), Human Press 2002)) or niosome. Most preferably, the gene delivery system of this invention is constructed by incorporating the β-PDC-encoding nucleotide sequence to lentiviruses. The Lentivirus is a type of retroviruses and enables transported genes to be expressed for long by integration with the stem cell genome. Furthermore, it may be infected to the fully differentiated cells as well as dividing cells.

To prepare the gene delivery system of the present invention, it is preferred that the β-ΡΙΧ-encoding nucleotide sequence is inserted into an appropriate expression construct. Preferably, the β-ΡΙΧ-encoding nucleotide sequence is operatively linked to a promoter in the expression construct. The term "operatively linked" refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.

According to the present invention, the promoter linked to the β-ΡΙΧ gene, without limitation, is operable in, preferably, animal, more preferably, mammalian cells, to control transcription of the β-ΡΙΧ gene. The promoter includes the promoters derived from the genome of mammalian cells or from mammalian viruses, for example, CMV (cytomegalovirus) promoter, the adenovirus late promoter, the vaccinia virus 7.5K promoter, SV40 promoter, HSV tk promoter, RSV promoter, EF1 alpha promoter, metallothionein promoter, beta-actin promoter, human IL-2 gene promoter, human IFN gene promoter, human IL-4 gene promoter, human lymphotoxin gene promoter and human GM-CSF gene promoter. Most preferably, the promoter is CMV promoter.

According to a preferred embodiment of the present invention, the polyadenylation sequence linked to the β-PJX gene comprises, but not limited to, bovine growth hormone terminator (Gimmi, E. R., et al., Nucleic Acids Res., 17:6983-6998(1989)), SV40-derived polyadenylation sequence (Schek, N., et al., Mol. Cell. Biol., 12:5386-5393(1992)), HIV-1 polyA (Klasens, B. I. F., et al., Nucleic Acids Res., 26:1870-1876(1998)), β-globin polyA (Gil, A., et al., Cell, 49:399- 406(1987)), or poliomavirus polyA (Batt, D. B. and G. G. Carmichael, Mol. Cell. Biol., 15:4783-4790(1995)).

The term "migration potential" as used herein, refers to the migratory ability of therapeutic cells to migrate to lesion sites.

According to the present invention, the amino acid sequence of SEQ ID NO: 2 encoded by the fi-PIXqene is very useful for improving neurological function by cell therapy through enhancing the migration potential of stem cells to lesion sites.

According to a preferred embodiment, the nucleotide sequence of this invention comprises a nucleotide of SEQ ID NO:l.

The nucleotide sequence of SEQ ID NO:l used in the present invention is the β-ΡΙΧ gene. Little has been known about biological functions of the β-ΡΙΧ gene in stem cell biology. Instead, it has established functions in T cell chemotaxis across reactive barriers (3), cancer cell migration (4), and neurite outgrowth (5).

The present invention may be applied to any of stem cells including, but not limited to, embryonic stem cells, adult stem cells, induced pluripotent stem cells, embryonic germ cells, embryonic carcinoma cells, preferably, multipotent adult stem cells, and more preferably, a mesenchymal stem cell (MSC).

In the present invention, the stem cell is contacted to the gene delivery system comprising a nucleotide sequence encoding β-ΡΙΧ having the amino acid sequence of SEQ ID NO:2, such that the migration potential of the stem cell is dramatically increased.

The contacting of stem cells to the gene delivery system is to transfect stem cells with the gene delivery system. The transfection may be performed in accordance with conventional techniques known to those skilled in the art. For example, stem cells may be incubated in a media for a sufficient period of time with suitable viral vectors carrying the β-PIXgene. The media for stem cells includes, but not limited to, Eagles's MEM (Eagle's minimum essential medium, Eagle, H. Science 130:432(1959)), a-MEM (Stanner, CP. et al._f Nat. New Biol. 230:52(1971)), Iscove's MEM (Iscove, N. et al., J. Exp. Med. 147:923(1978)), 199 medium (Morgan et al., Proc. Soc. Exp. Bio. Med., 73:1(1950)), CMRL 1066, RPMI 1640 (Moore et al., J. Amer. Med. Assoc. 199:519(1967)), F12 (Ham, Proc. Natl. Acad. Sci. USA 53:288(1965)), F10 (Ham, R.G. Exp. Cell Res. 29:515(1963)), DMEM (Dulbecco's modification of Eagle's medium, Dulbecco, R. et al., Virology 8:396(1959)), mixture of DMEM and F12 (Barnes, D. et al., Anal. Biochem. 102:255(1980)), Way-mouth's MB752/1 (Waymouth, C. J. Natl. Cancer Inst. 22:1003(1959)), McCoy's 5A (McCoy, T.A., et al., Proc. Soc. Exp. Biol. Med. 100:115(1959)) and MCDB series (Ham, R.G. et al., In Vitro 14:11(1978)).

In still another aspect of this invention, there is provided a stem cell transformed with the composition of the present invention.

As the composition for improving the migration potential of stem cells and applicable stem cells are mentioned hereinabove, they are omitted herein to avoid undue redundancy.

In still another aspect of this invention, there is provided a composition for treating neurological diseases comprising the stem cell of the present invention.

The composition of this invention may be provided as a pharmaceutical composition. The pharmaceutical composition of this invention includes a pharmaceutically acceptable carrier besides the active ingredient compound. The pharmaceutically acceptable carrier contained in the pharmaceutical composition of the present invention, which is commonly used in pharmaceutical formulations, but is not limited to, includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, rubber arable, potassium phosphate, arginate, gelatin, potassium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oils. The pharmaceutical composition according to the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent and a preservative. Details of suitable pharmaceutically acceptable carriers and formulations can be found in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition according to the present invention may be administered via the routes used commonly in gene therapy and preferably, administered parenterally, i.e., by intravenous, intraperitoneal, intramuscular, subcutaneous, or local administration. For example, the pharmaceutical composition may be administered intrathecally or intracerebroventricularly.

A suitable dosage amount of the pharmaceutical composition of the present invention may vary depending on pharmaceutical formulation methods, administration methods, the patient's age, body weight, sex, pathogenic state, diet, administration time, administration route, an excretion rate and sensitivity for a used pharmaceutical composition and physicians of ordinary skill in the art can determine an effective amount of the pharmaceutical composition for desired treatment. Generally, a daily dosage of the pharmaceutical composition of the present invention comprises 1 x 10² - 1 x 10¹⁰ cells.

According to the conventional techniques known to those skilled in the art, the pharmaceutical composition of the present invention may be formulated with pharmaceutically acceptable carrier and/or vehicle as described above, finally providing several forms a unit dose form and a multi-dose form. Non-limiting examples of the formulations include, but not limited to, a solution, a suspension or an emulsion in oil or aqueous medium, an extract, an elixir, a powder, a granule, a tablet and a capsule, and may further comprise a dispersion agent or a stabilizer.

The diseases treated by the composition of the present invention include any of neurological diseases caused by pathological or physical demage of nervous tissues, and preferably, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), cerebral ischemia, cerebral hemorrhage, spinal cord injury, motor neuron disease, demyelinating disease, Huntington's disease, and more preferably, ischemic stroke.

In still another aspect of this invention, there is provided a method for evaluating the migration potential of a stem cell, comprising measuring the expression level of the nucleotide sequence of SEQ ID NO:l in a biological sample.

The term "biological sample" as used herein refers to materials containing stem cells with biological activities to be analyzed.

The measurement of the expression level of the nucleotide of SEQ ID NO:l may be performed by any of methods for evaluating the gene expression level generally known to those skilled in the art. For example, it may be performed through measuring mRIMA level transcribed by DNA molecules, or measuring protein level translated by the mRNA.

The measurement of mRNA expression level may be carried out by amplification reaction using mRNA in the sample as template, and primers binding to mRNA or cDNA. For obtaining mRNA molecules, total RNA is isolated from samples. The isolation of total RNA may be performed by various methods (Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press(2001); Tesniere, C. et al., Plant Mol. Biol. Rep., 9:242 (1991); Ausubel, F.M. et al., Current Protocols in Molecular Biology, John Willey & Sons (1987); and Chomczynski, P. et al., Anal. Biochem. 162:156 (1987)). For example, total RNA in cells may be isolated using Trizol. Afterwards, cDNA molecules are synthesized using mRNA molecules isolated and then amplified. Since total RNA molecules used in the present invention are isolated from human samples, mRNA molecules have poly-A tails and converted to cDNA by use of dT primer and reverse transcriptase (PNAS USA, 85:8998(1988); Libert F, et al., Science, 244:569(1989); and Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press(2001)). cDNA molecules synthesized are then amplified by amplification reactions.

A variety of DNA polymerases can be used in the extension step of the present methods, which includes "Klenow" fragment of E. coli DNA polymerase I, a thermostable DNA polymerase, and bacteriophage T7 DNA polymerase. Preferably, the polymerase is a thermostable DNA polymerase which may be obtained from a variety of bacterial species, including Thermus aquaticus (Taq), Thermus thermophilus (Tth), Thermus filiformis, Thermis flavus, Thermococcus literalis, and Pyrococcus sp. Most preferably, the polymerase obtained from Pyrococcus sp may be used, and the present inventors used Pyrobest™ DNA polymerase (TaKaRa, Japan).

When a polymerization reaction is being conducted, it is preferable to provide the components required for such reaction in excess in the reaction vessel. Excess in reference to components of the extension reaction refers to an amount of each component such that the ability to achieve the desired extension is not substantially limited by the concentration of that component. It is desirable to provide to the reaction mixture an amount of required cofactors such Mg²⁺, dATP, dCTP, dGTP, and dTTP in sufficient quantity to support the degree of the extension desired. All of the enzymes used in polymerization reaction may be in active state at equivalent reaction conditions. In fact, buffers give the optimal reaction conditions to all enzymes. Therefore, the polymerization process of the present invention can be performed in a single reactant without change of condition such as addition of other reactants.

Annealing or hybridization in the present invention is performed under stringent conditions that allow for specific binding between the primer and the target nucleotide sequence. Such stringent conditions for annealing will be sequence- dependent and varied depending on environmental parameters.

Amplified cDNA of the nucleotide of SEQ ID NO: l is analyzed by suitable methods to measure the expression level. For example, the resulting products are separated by gel electrophoresis and the band patterns are analyzed.

The analysis for evaluating the expression amounts of β-ΡΙΧ protein may be conducted in accordance with immunoassay methods known to one skilled in the art. The immunoassay format includes, but is not limited to, radioimmunoassay, radioimmuno-precipitation, immunoprecipitation, enzyme-linked immunosorbent assay (EUSA), capture-ELISA, inhibition or competition assay, sandwich assay, flow cytometry assay, immunofluorescence staining assay and immunoaffinity assay.

The immunoassay or immunostaining procedures can be found in Enzyme

Immunoassay, E. T. Maggio, ed., CRC Press, Boca Raton, Florida, 1980; Gaastra, W., Enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology, Vol. 1, Walker, J.M. ed., Humana Press, NJ, 1984; and Ed Harlow and David Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999.

For example, according to the radioimmunoassay method, the radioisotope e.g., C¹⁴, 1¹²⁵, P³² and S³⁵) labeled antibody may be used to detect the β-ΡΙΧ protein.

According to the ELISA method, the specific example of the present method may further comprise the steps of: (i) coating a surface of a solid substrate with a cell lysate of interest; (ii) incubating the cell lysate to be analyzed with β-ΡΙΧ protein as a primary antibody; (iii) incubating the resultant of step (ii) with a secondary antibody conjugated to an enzyme; and (iv) measuring the activity of the enzyme.

The solid substrate coated with the primary antibody is a hydrocarbon polymer {e.g., polystyrene and polypropylene), a glass, a metal or a gel, and most preferably, a microtiter plate.

The secondary antibody conjugated to an enzyme includes, but is not limited to, an enzyme catalyzing colorimetric, fluorometric, luminescence or infra-red reactions, for example, alkaline phosphatase, β-galactosidase, horseradish peroxidase, luciferase and cytochrome Ρ₄₅₀. Where using alkaline phosphatase, bromochloroindolylphosphate (BCIP), nitro blue tetrazolium (NBT) and ECF (enhanced chemifluorescence) may be used as a substrate; in the case of using horseradish peroxidase, chloronaphtol, aminoethylcarbazol, diaminobenzidine, D- luciferin, lucigenin (bis-yV-methylacridinium nitrate), resorufin benzyl ether, luminol, Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine, Pierce), HYR (p- phenylenediamine-HCI and pyrocatechol), TMB (3,3,5,5-tetramethylbenzidine), ABTS (2,2'-Azine-di[3-ethylbenzthiazoline sulfonate]), £>-phenyldiamine (OPD) and naphtol/pyronin, glucose oxidase and tlMBT (nitroblue tetrazolium) and m-PMS (phenzaine methosulfate) may be used as a substrate.

According to the capture-ELISA method, the specific example of the present method may comprise the steps of: (i) coating a surface of a solid substrate with an antibody of the β-ΡΙΧ protein as a capturing antibody; (ii) incubating the capturing antibody with a cell sample; (iii) incubating the resultant of step (ii) with a detecting antibody having a fluorescent label which reacts with the β-ΡΙΧ protein specifically; and (iv) measuring the signal generated from the label.

The detecting antibody includes a substance generating a detectable signal. The signal-generating substance bound to antibody includes, but is not limited to, chemical (e.g., biotin), enzyme (alkaline phosphatase, β-galactosidase, horseradish peroxidase and Cytochrome P₄₅₀), radio-isotope (e.g., C¹⁴, I¹²⁵, P³² and S³⁵), fluorescent (e.g., fluoresin), luminescent, chemiluminescent and FRET (fluorescence resonance energy transfer) substances. Various methods for labels and labelings are described in Ed Harlow and David Lane, Using Antibodies:A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999. The analysis for measuring the activity or the signal of final enzyme in the ELISA and capture-ELISA method may be carried out by various methods known to those skilled in the art. The signal detection permits to a quantitative or qualitative analysis of the β-ΡΙΧ protein. For example, the signal of each biotin- and luciferase- labeled protein may be feasibly detected using streptavidin and luciferin.

The migration potential of a stem cell may be predicted by analyzing the final strength of the signal obtained by above-mentioned immunoassay processes.

In addition, western blot analysis or immunocellularchemical assay with β-ΡΙΧ specific antibodies may also be performed. Concretely, transformed cells are incubated with anti-β-ΡΙΧ monoclonal antibodies and then incubated with secondary antibodies conjugated with labels such as tetramethylrhoodamine isothiocyanate (T ITC). Thereafter, the intensity of label detection is compared with negative controls to evaluate the expression level of β-ΡΙΧ.

If the expression level of the nucleotide of SEQ ID NO:l in the stem cells to be analyzed is measured to be lower than normal stem cells, they are determined to lack the migration potential (or cell therapeutic efficacy)

In still another aspect of this invention, there is provided a method for screening an adjuvant for cell therapy improving the migration potential of a stem cell to treat neurological diseases, comprising the steps of:

(a) contacting a test substance to a cell comprising the nucleotide sequence of SEQ ID NO:l; and

(b) measuring the expression level of the nucleotide of SEQ ID NO: 1, wherein when the expression level of the nucleotide of SEQ ID NO: 1 is increased, the test substance is determined the adjuvant for cell therapy improving the migration potential of the stem cell to treat neurological diseases.

According to the present method, the cells containing the nucleotide of SEQ ID NO:l are first contacted to test substances to be analyzed. Preferably, the cells of the present method are human stem cells, and most preferably, human mesenchymal stem cells. The term "substance" used herein in conjunction with the present screening method refers to a material to be tested in the present method for analyzing its influence on the expression level of the nucleotide of SEQ ID NO:l. The substance includes chemical compounds, peptides, antibody proteins, nucleotides, antisense-RNA, siRNA (small interference RNA) and extract of natural source, but not limited to.

Afterwards, the expression level of the nucleotide sequence of SEQ ID NO:l is measured. Where the expression level of the nucleotide sequence of SEQ ID NO:l is measured to be increased, the substance is determined the adjuvant for cell therapy improving the migration potential of a stem cell to treat neurological diseases..

The features and advantages of the present invention will be summarized as follows:

(a) The present invention provides a composition for improving the migration potential of a stem cell, a method for evaluating the migration potential of a stem cell and a method for screening an adjuvant for cell therapy improving the migration potential of a stem cell.

(b) The present invention may be effectively used for enhancing the efficacy of neurological disease-treatment by inducing therapeutic stem cells to migrate efficiently to the lesion site.

The present invention will now be described in further detail by examples. It would be obvious to those skilled in the art that these examples are intended to be more concretely illustrative and the scope of the present invention as set forth in the appended claims is not limited to or by the examples.

EXAMPLES MATERIALS AND METHODS

1. Animal preparation and ischemic surgery.

All animal procedures were performed in accordance with the Hanyang University guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Hanyang University. Sprague-Dawley (SD) rats, weighing 210 to 245 g, were purchased from Biogenomics Inc. (Seoul, Korea).

After periods of adaptation and pretraining for behavioral tests, the left middle cerebral arteries (MCA) of 95 SD rats weighing 295 to 360 g were occluded for two hours using the intraluminal filament technique described in our previous study (1, 2). Throughout and following the surgery, rats were deeply anesthetized by intraperitoneal injection of tiletamine (25 mg/kg) and zolazepam (25 mg/kg, Zoletil, Yuhan Corp., Seoul, Korea) together with xylazine (10 mg/kg, Rompun, Bayer, Frankfurt, Germany) and body temperature was maintained at 36.6 ± 0.5° C with a thermistor-controlled heating pad. Physiological variables (pH, pC0₂, p0₂ and hematocrit) were measured in 0.1 ml aliquots of arterial blood obtained from a right femoral catheter using a blood-analysis system (International Technidyne, NJ, USA). Arterial pressure was monitored from the arterial catheter with a strain-gauge transducer (LIFE KIT DX-360; Nihon Kohden, Tokyo, Japan) and amplifier (MacLab Bridge Amplifier, ADInstruments Pty Ltd., Castle Hill, Australia). Phasic pressure, mean arterial pressure (MAP), and heart rate (HR) were recorded at a sampling rate of 200/s using a data acquisition system and laboratory computer (MacLab 8 analog- to-digital converter and Macintosh Computer). For the cerebral blood flow (CBF) study, a wire-type probe (0.3 mm diameter; Unique Medical, Tokyo, Japan) connected to a Laser Doppler flow meter (ALF21; Advance, Tokyo, Japan) was inserted 6 mm through a small burr hole placed 2 mm lateral to the bregma, such that the probe lay against the dural surface overlying the frontal cortex. Measurements were taken at a depth of 6 mm from the cortex to evaluate the deep ischemic core regions (caudate and putamen of the affected hemisphere).

After a 2-h occlusion, reperfusion was performed as described in our previous reports (1, 3).

A sham surgery was performed in additional 10 rats by introducing and immediately withdrawing a thread into the left common carotid artery. Other procedures in the sham group were identical to those used in the ischemic surgery.

2. Labeling of MSCs with feridex and protamine sulfate.

The commercially available Feridex IV (TAFJOOIM Pharmaceutical Co., Ltd.,

Seoul, Korea Mfd by Advanded Managnetics, Inc. Combridge, MA, USA)) has a total iron content of 11.2 mg/mL (11.2 iron pg/pL). Protamine sulfate (Sigma, USA) was prepared as a fresh stock solution of 1 mg/mL in distilled water at the time of use. Feridex IV at a concentration of 25 pg/mL was put into a tube containing serum-free DMEM medium (Gibco invitrogen, Carlsbad, CA, USA) containing lOOunit/ml penicillin and lOOmg/ml streptomycin. Protamine sulfate was then added to the solution at lug/ml concentrations. The solution (FE-Pro complexes) containing feridex IV and protamine sulfate was mixed for 60 minutes. And then, the solution was added to the adherent hMSC cell culture. FE-Pro complexes were added directly to the cells, incubated for 2 hours, and then an equal volume of the complete medium was added to the cells. The cell was then incubated overnight.

3. MSCs grafting in ischemic stroke model rats.

To examine whether the migratory activity of implanted MSCs differs according to their origin, 4 kinds of MSCs such as ALS-MSCs from ALS patients (IRB- No), C-MSCs purchased from Cambrex, UCB-MSCs from umbilical cord blood (IRB- No), and hUC-MSCs from the endothelial/subendothelial layer of human umbilical cord (IRB-No) were injected into each 18 SD rats using stereotaxic surgery (ALS- MSC, C-MSC, UCB-MSC, and hUC-MSC groups, respectively) two weeks after intraluminal left MCA occlusion (MCAo). An equivalent volume of PBS was similarly injected into the remaining 18 rats (PBS group). All these groups were not statistically different in body weight (from 317.3 ± 22.0 g to 324.3 ± 14.1 g) or motor and behavioral deficit score (from 6.6 ± 0.7 to 7.0 ± 0.8) just before the implantation. The animals were anesthetized with pentobarbital sodium (50 mg/kg, IP). We implanted 5 μΙ suspensions of 6 x 10^s each kind of MSCs, and PBS in one site contralateral (Site: AP = +0.7, R = +2, V = -5.5) to the lesion. The suspensions were delivered in 2 min, and the syringe was then left in place for an additional 2 min. For the control group, 5 μΙ of PBS was used. The rats in both groups received daily immunosuppression with cyclosporine A (10 mg/kg body weight, subcutaneously; Sandoz, Switzerland) from two days before cell transplantation until the end of the study.

4. Behavioral tests of ischemic stroke model rats.

All animals were trained for neurobehavioral assessment for seven days before MCAO. The neurologic examination was performed daily to assess a neurologic deficit score (NDS) comprised of consciousness (0, normal; 1, restless; 2, lethargic; 3, stuporous; 4, death), gait (0, normal; 1, paw adduction; 2, unbalanced walking; 3, circling; 4, unable to stand; 5, no movement), limb tone (0, normal; 1, spastic; 2, flaccid), and pain reflex (0, normal; 2, hypoactive; 4, absent) at 2 hrs and 7, 14 (just before implantation), 21, 28, and 35 days after MCAO by an investigator who was blind to the experimental groups (4).

5. In vivo MRI study

In MRI studies, all the rats were anesthetized with pentobarbital sodium (50 mg/kg IP) and fixed to a Taoka rat cradle. They maintained respiration without assistance. A 3-inch-diameter circular receive-only surface coil was plated under the head of each rat, with the center of the coil located at the midpoint of the midline between the ear-ear and eye-eye lines. Body temperature was kept at 37 °C with a heating pad. The temperature of the MR imaging room was controlled to roughly 27 °C, and MR imaging was performed with 3T clinical instrument (Philips, Netherland) with animal coil (Shanghai Chenguang Medical TechnologiesCo., LTD, China). For the elucidation of the extent of ischemic lesion, Fluid Attenuated Inversion Recovery (FLAIR) images were obtained using the spin-echo technique (TR= 11,000 ms and TE=125 ms) between the vertex of the head and the bottom of the brain. Other imaging parameters included 0.7mm slice thickness, point resolution of 284 X286 μΐη and number of acquisitions = 1. For T2* weighted images of a rat brain with Multiplanar Gradient-Recalled (MPGR) pulse sequence, the following parameters were adopted : TR= 596 ms, TE = 16 ms, section thickness = 0.7mm, point resolution : 292 X 290 μπι and number of acquisitions = 1.

6. Immunohistochemistry of human mitochondria.

To confirm whether the low signal intensities shown the MPGR images are due to the implanted MSCs, we sacrificed three rats from the C-MSC group 35 days after the implantation. Anti-human mitochondria monoclonal antibody (1:100, Chemicon, Temecula, CA, USA) was used as a primary antibody. Coronal sections (20 pm thickness) of the brain were prepared and incubated with one of the primary antibody for 72 hours at 4oC. The sections were washed three times for 5 min each to remove unbound antibodies and then incubated for 24 hours with the appropriate secondary antibody conjugated to TRITC. Unbound secondary antibody was removed with three rinses of 5 min each. After air-drying, coverslip was applied to the slides with Vector Shield mounting medium. As a negative control, the above procedures were repeated without primary antibodies. Cell staining was not observed in the negative control. A laser-scanning confocal microscopy system mounted onto a LEICA DMIRE2 microscope (Germany) was used. For immunofluorescence-labeled slides, red (TRITC) fluorochromes on the slides were excited by the laser beam at 557-nm, and emissions were acquired sequentially with a photomultiplier tube through 576-nm emission filters, respectively. The implanted stem cells were stained with antibody for human mitochondria.

7. Production and propagation of the recombinant lentivirus.

To confirm the role of β-PIX ^'m the migration of stem cells in vivo, we used lentiviral DNAs bearing the β-ΡΙΧ specific shRNA or cDNA. The lentiviral DNA containing the shRNA were purchased from Open biosystems with Trans-Lentiviral™ GIPZ packaging System (OpenBiosystem, USA). The viral stocks were produced following the manufacturer's instructions. For β-PIXgene over-expression, the β-ΡΙΧ and GFP cDNAs were subcloned into the pLenti6/V5-D-TOPO (Invitrogen, USA) and confirmed by sequencing. The recombinant β-ΡΙΧ- or GFP-Lentivirus was produced following the manufacturer's instructions (Invitrogen, USA) with minor modification. To determine viral concentration of the viral stocks, the viral supernatants were serial diluted and transduced into hBM-MSC or HT1080 cells with 6 pg/ml Polybrene (Sigma, USA) and then cells were selected by 6 pg/ml Blasticidin (Invitrogen, USA) (M. Kimura et al., 1994) for 10 days. The remaining cells were stained with crystal violet and colonies were counted under the microscopy. For the lentivirus carrying GFP gene, the virus was transduced into hBM-MSCs following the described above. GFP-transduced hBM-MSCs were growth for 3 days and fixed in 1% paraformaldehyde and the fluorescence activities are read using by FACS machine. We obtained 6 x 10^s TU (transduction unit)/ml of β-ΡΙΧ gene-transduced viral particals in HT1080 cell, 2 x 10^s TU/ml in hBM-MSCs and 1 x 10^s TU/ml of the shRNA-transduced viral particals in hBM-MSCs. To obtain the high concentration of recombinant virus, the virus-containing supernatants were harvested using ultracentrifugation at 28,000g for 90 min and stored -80°C.

8. Lentiviral infection. hBM-MSCs were seeded at a density of 8 x 10^s cells per 75T flasks. MSCs were exposed to 0, 2 or 5 multiplicity of infection (MOI) of the infectious viral particles containing the shRNA, GFP or β-PIXgene in 15 ml DMEM media at 37°C for overnight and the media were removed and cells washed once with DMEM. The cells were then incubated for 4 days with normal medium, and alteration of migratory activity in β-ΡΙΧ gene-modified MSCs was evaluated in vitro and in vivo condition by using the above described methods.

9. Cell migration assay.

Cell migration was examined by a QCM chemotaxis (8 pm pore size) 96-well migration assay (Chemicon, USA). Briefly, the migration chambers were coated with 50 μΙ of HA (5 mg/ml) and air-dried overnight. 5 X 10⁴ MSCs in 100 μΙ serum-free medium were seeded in the migration chamber. The lower chamber contained 150 μΙ of serum-free medium containing 10% bovine serum albumin. The plates were incubated at 37°C in 5% C0₂ for 24 hrs. After incubation, MSCs suspended in media in the migration chamber were gently removed by flipping out the medium. The cells adhering to the top side of the membrane were removed by scratching with a cotton applicator, and the migration chamber plate was then placed onto a new 96-well feeder tray containing 150 μΙ of prewarmed cell detachment solution in the wells. After 30 minutes of incubation at 37°C, 50 μΙ of a lysis buffer/dye solution was added to the feeder tray and incubated 15 minutes at room temperature. The mixture (150 μΙ) was then transferred to a new 96-well plate and the plate was read with a fluorescence plate reader using a 480/520-nm filter set (HTS 7000 Bioassay reader), which was performed according to the manufacturer's instructions (5).

10. Real time PCR and Reverse Transcription-Polymerase Chain Reaction (RT-PCR).

To investigate the difference of the level of mR A for β-ΡΙΧ, four kinds of MSCs such as ALS-MSCs, C-MSCs, UCB-MSCs, and hUC-MSCs were harvested at near confluence, and total RNAs were extracted using Trizol reagent following the manufacturer's instructions (Invitrogen, USA). 5 μg total RNA was reverse- transcribed using RevertAid™ M-MuLV reverse transcriptase (MBI Fermentas, USA), 0.2 pg random primer (Invitrogen, USA), 1 mM dNTPs, and the supplied buffer. The first strand cDNA was amplified using Taq DNA polymerase (MBI Fermentas, MD) with 5'-AAGCGCAAACCTGAACGGAA-3' (upstream) and 5 - TCACCTCAGAACTGGTCTTCA-3' (downstream) as primers for β-ΡΙΧ and 5 - TGCTATCCCTGAAAGCCTCTG-3' (upstream) and 5'-AGCTGGGGTGATGAAGCTGTA-3' (downstream) primers for β-actin. For cloning human β-ΡΙΧ gene, the first strand cDNA from wild type MSCs was amplified using PyrobestTM DNA polymerase (TaKaRa, Japan) with primers 5'-CACCATGACCGATAATAGCAACAA -3' (forward) and 5'-TCACCTCAGAACTGGTCTTCA-3' (reverse). The PCR cycling parameters were as follows: initial denaturation at 94°C for 2 min; 30 cycles of 30 s at 94°C for denaturation, 30 s at 55°C for primer annealing, and 1 min at 72°C for extension; and final extension at 72°C for 10 min. After amplification, the PCR products were resolved by agarose gel electrophoresis. For quantification of gene transcripts, real time PCR was performed in 96-well plates, with a final volume of 20 μΙ/well using the SYBR Green PCR kit (Applied Biosystems, Inc., Foster City, CA, USA). Each reaction volume contained 10 μΙ of SYBR Green mix (2x concentrated), 6 μΙ of H₂0, 1 μΙ of cDNA sample, and 3 μΙ of primer mix (sense and antisense primers, each 2 pmol/μΙ). The real time PCR cycling parameters were as follows: initial denaturation at 95°C for 10 min; 40 cycles of 15 sec at 95°C for denaturation, 1 min at 60°C for primer annealing and extension. After the amplification protocol a dissociation curve was constructed by ramping the temperature from 60 to 90°C. The resulting Ct values were converted to absolute amounts of cDNA present in the sample (E-Ct) (37). To correct for differences in cDNA amounts between samples, we normalized the target PCR to the geometric mean values of PCRs on a set of reference genes.

11. Quantitative PCR array- Two plates of the RT2 Profiler PCR array for human tumor metastasis (PAHS- 028; SuperArray Bioscience Corporation, Frederick, MD, USA) were used to compare Q-PCR validated cDNA samples of normal- and ALS-MSCs. cDNA equivalent to 1 pg of total RNA was used for each plate. The cDNA was mixed with the RT2 SYBR Green/ROX Q-PCR Master Mix, and 25 μΙ was added to each of the wells containing different primers. The plate was run under the same conditions as described above. The outcome was normalized against the set of reference genes used for the Q-PCR. Analysis using the references genes present on the array yielded a comparable outcome.

12. Western blotting and Immunocytochemistry. To assess the difference of the protein level of β-ΡΙΧ, western blot and immunocytochemistry were performed with a specific antibody for β-ΡΙΧ (Cell signaling, USA).

First, western blot was performed with the antibody (1:1000) according to previously described procedures (28). 5 X 10⁶ MSCs cultured for 24 hrs were used for western blot. All figures are representative of at least five independent experiments. And then, immnucytochemistry was performed. After culture for 24 hrs, the cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 20 min at 4°C. Following several washes, the cells were permeabilized with 0.5% Triton X-100 for 20 min. After incubation in 5% BSA in PBS for one hour, the cells were reacted with anti-β-ΡΙΧ monoclonal antibody (1:100) overnight at 4°C. Following incubation, the cells were washed three times for 5 min each to remove unbound antibodies and then incubated with the appropriate secondary antibody conjugated to TRITC for 20 min at room temperature. Unbound secondary antibody was removed by three rinses lasting 10 min each. The coverslip was overlaid with Vector Shield mounting medium (Vector Laboratories, CA, USA). As a negative control, the above procedures were also carried out with mouse IgG antibody (Kamiya Biomedical, WA, USA).

13. Comparison of neurotrophic factors.

The present inventors hypothesized that reduced β-ΡΙΧ expression could decrease the secretion of neurotrophic factors that are important for the improvement of motor functions by MSCs. A total of 1 X 10⁴ ALS-MSCs or C-MSCs were plated in 96-well plates. After incubation for 24 hrs, each culture supernatant was divided into 200 μί triplicate samples. Vascular endothelial growth factor (VEGF), stromal cell-derived factor-la (SDF-la), and brain-derived neurotrophic factor (BDNF) levels were measured in the culture supernatants with BDNF, SDF-la, and VEGF ELISA kits (R&D Systems, USA) by following the manufacturer's instructions (2). When compared with C-MSCs, concentrations of SDF-la (A) and VEGF (B) were significantly decreased in culture supernatant of ALS-MSCs but concentration of BDNF (C) was not. The level of these neurotrophic factors is not affected by genetic modulation of β-ΡΙΧ.

RESULTS

1. Comparison of migratory capacity of MSCs derived from different origins. We followed the migration of Ferumoxides-labeled MSCs in rat brains using in vivo MR imaging. MSCs were derived from different origins including amyotrophic lateral sclerosis patient bone marrow (ALS-MSC), normal human bone marrow of which MSCs were purchased from Cambrex® (C-MSC), human umbilical cord tissue (hUC-MSC), and umbilical cord blood (UCB-MSC). The path of migratory MSCs in T2*-weighted images of the ischemic rat brain can be easily tracked by observing the hypointense voxels (i.e., dark regions) (Fig. 5). Surprisingly, the ALS-MSC lacked migratory capability, while all other MSC populations migrated to the lesion sites (Fig. la). Out of 10 rats in each group, hypointense voxels were detected in seven rats of the C-MSC group, eight of the hUC-MSC group, nine of the UCB-MSC group, and only one of the ALS-MSC group. This negates the assumption in the field of MSC transplantation that all sources of MSCs possess migratory capacity in the brain. The migratory behaviours of ALS-MSC and C-MSCs in MSC-implanted rat brains were followed up to 35 days after transplantation and after 35 days, the ALS-MSCs did not show migratory activity compared to C-MSCs (Fig. lb).

The results of the MR studies for the in vivo migratory capacity of different MSC populations was also corroborated by in vitro transwell chemotaxis assays as shown in Figure lc. Moreover, the recovery of motor function of rats with ischemic stroke that were implanted with C-MSCs, hUC-MSCs, or UCB-MSCs significantly improved, while ALSMSCs failed to support motor function improvement (Fig. 6).

2. Behavioral tests of ischemic stroke model rats.

A decrease in the neurologic deficit score (NDS) indicates an improvement in behavioral functions. As shown in Fig. 6, there was no difference between the five groups prior to implantation, but the NDS was significantly lower in the C-MSC, hUC- MSC, and UCB-MSC groups (N=10 in each group) than in the ALS-MSC group (N=10) from 7 days after implantation although statistically significant difference was shown from 21 days after implantation. In other words, C-MSCs, hUC-MSCs, and UCB-MSCs significantly improved behavioral functions of ischemic stroke rats but ALS-MSCs did not.

3. Quantitative PCR array. Quantitative PCR was used to identify genes that are necessary for cancer cell migration and play a role in MSC migration to lesion sites (Fig. 7). The expression of genes such as VEGFA, CTSK, β-ΡΙΧ, and MTSSl were markedly lower in ALS-MSCs than C-MSCs (Fig. 2a). VEGFA was used as internal control because it is known to be down-regulated in ALS patients (2). The fi-PJX gene expression was reduced 7.58 fold, yet has no known functions in stem cell biology. Instead, it has established functions in T cell chemotaxis across reactive barriers (3), cancer cell migration (4), and neurite outgrowth (5).

Table 1. Names of migration associated genes which were investigated in this study

Unigene GeneBank Symbol Description

Hs.158932 NM_000038 APC Adenomatous polyposis coli

Hs.100426 NM_015399 BRMS1 Breast cancer metastasis suppressor 1

Hs.251526 NM_006273 CCL7 Chemokine (C-C motif) ligand 7

Hs.502328 NM_000610 CD44 CD44 molecule (Indian blood group)

Hs.461086 NM_004360 CDH1 Cadherin 1, type 1, E-cadherin (epithelial)

Hs.116471 NM_001797 CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast)

Hs.171054 NM_004932 CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney)

Hs.512599 NM_000077 CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, pl6, inhibits CDK4)

Hs.162233 NM_001273 CHD4 Chromodomain helicase DNA binding protein 4

Hs.508716 NM_001846 C0L4A2 Collagen, type IV, alpha 2

Hs.143212 NM_003650 CST7 Cystatjn F (leukocystatjn)

Hs.208597 NM_001328 CTBP1 C-terminal binding protein 1

Hs.534797 NM_001903 CTNNAl Catenin (cadherin-associated protein), alpha 1, 102kDa

Hs.632466 NM_000396 CTSK Cathepsin K

Hs.716407 NM_001912 CTSL1 Cathepsin LI

Hs.522891 NM_000609 CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)

Hs.593413 NM_003467 CXCR4 Chemokine (C-X-C motif) receptor 4

Hs.22393 NM_003677 DENR Density-regulated protein

Hs.523329 NM_004442 EPHB2 EPH receptor B2

Hs.434059 NM_001986 ETV4 Ets variant 4

Hs.374477 N _005243 EWSR1 Ewing sarcoma breakpoint region 1 Hs.481371 NM_005245 FAT1 FAT tumor suppressor homolog 1 (Drosophila)

Hs.165950 NM_002011 FGFR4 Fibroblast growth factor receptor 4

Hs.646917 NM_002020 FLT4 Fms-related tyrosine kinase 4

Hs.203717 NM_002026 FN1 Fibronectin 1

Hs.333418 NM_014164 FXYD5 FXYD domain containing ion transport regulator 5

Hs.82963 NM_000825 GNRH1 Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone)

Hs.208229 NM_032551 ISS1R KISS1 receptor

Hs.396530 NM_000601 HGF Hepatocyte growth factor (hepapoietin A; scatter factor)

Hs.44227 NM_006665 HPSE Heparanase

Hs.37003 NM_005343 HRAS V-Ha-ras Harvey rat sarcoma viral oncogene homolog

Hs.90753 NM_006410 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa

Hs.160562 NM_000618 IGF1 Insulin-like growth factor 1 (somatomedin C)

Hs.83077 NM_001562 IL18 Interleukin 18 (interferon-gamma-inducing factor)

Hs.126256 NM_000576 IL1B Interleukin 1, beta

Hs.846 NM_001557 IL8RB Interleukin 8 receptor, beta

Hs.524484 NM_002206 ITGA7 Integrin, alpha 7

Hs.218040 NM_000212 ITGB3 Integrin, beta 3 (platelet glycoprotein Ilia, antigen CD61)

Hs.527778 NM_002231 CD82 CD82 molecule

Hs.95008 NM_002256 KISS1 KiSS-1 metastasis-suppressor

Hs.505033 NM_004985 KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

Hs.449909 NM_002295 RPSA Ribosomal protein SA

Hs.599039 NM_006500 MCAM Melanoma cell adhesion molecule

Hs.484551 NM_002392 MDM2 Mdm2 p53 binding protein homolog (mouse)

Hs.132966 NM_000245 MET Met proto-oncogene (hepatocyte growth factor receptor)

Hs.444986 NM_006838 METAP2 Methionyl aminopeptidase 2

Hs.651869 NM_002410 MGAT5 Mannosyl (alpha-l,6-)-glycoprotein beta-l,6-N-acetyl-glucosaminyltransferase

Hs.2258 NM_002425 MMP10 Matrix metallopeptidase 10 (stromelysin 2)

Hs.143751 NM_005940 MMP11 Matrix metallopeptidase 11 (stromelysin 3)

Hs.2936 NM_002427 MMP13 Matrix metallopeptidase 13 (collagenase 3)

Hs.513617 NM_004530 MMP2 Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase,

72kDa type IV collagenase)

Hs.375129 NM_002422 MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase)

Hs.2256 NM_002423 MMP7 Matrix metallopeptidase 7 (matrilysin, uterine)

Hs.297413 NM_004994 MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)

Hs.525629 NM_004689 MTAl Metastasis associated 1

Hs.700429 NM_014751 MTSSl Metastasis suppressor 1

Hs.202453 NM_002467 MYC V-myc myelocytomatosis viral oncogene homolog (avian)

Hs.437922 NM_005376 MYCL1 V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian)

Hs.187898 NM_000268 NF2 Neurofibromin 2 (merlin)

Hs.118638 NM_000269 NME1 Non-metastatic cells 1, protein (NM23A) expressed in

Hs.463456 NM_002512 NME2 Non-metastatic cells 2, protein (NM23B) expressed in

Hs.9235 NM_005009 NME4 Non-metastatic cells 4, protein expressed in

Hs.279522 NM_006981 NR4A3 Nuclear receptor subfamily 4, group A, member 3 Hs.466871 NM_002659 PLAUR Plasminogen activator, urokinase receptor

Hs.409965 NM_002687 PNN Pinin, desmosome associated protein

Hs.500466 NM_000314 PTEN Phosphatase and tensin homolog

Hs.408528 NM_000321 RBI Retinoblastoma 1

Hs.494178 NM_006914 RORB RAR-related orphan receptor B

Hs.436687 NM_003011 SET SET nuclear oncogene

Hs.12253 NM_005901 SMAD2 SMAD family member 2

Hs.75862 NM_005359 SMAD4 SMAD family member 4

Hs.195659 NM_005417 SRC V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)

Hs.514451 NM_001050 SSTR2 Somatostatin receptor 2

Hs.371720 NM_003177 SYK Spleen tyrosine kinase

Hs.475018 NM_005650 TCF20 Transcription factor 20 (AR1)

Hs.645227 NM_000660 TGFB1 Transforming growth factor, beta 1

Hs.633514 NM_003255 TIMP2 TIMP metallopeprjdase inhibitor 2

Hs.644633 NM_000362 TIMP3 TIMP metallopeprjdase inhibitor 3

Hs.591665 NM_003256 TIMP4 TIMP metallopeptidase inhibitor 4

Hs.478275 NM_003810 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10

Hs.654481 NM_000546 TP53 Tumor protein p53

Hs.155942 NM_002420 TRPM1 Transient receptor potential cation channel, subfamily M, member 1

Hs.160411 NM_000369 TSHR Thyroid stimulating hormone receptor

Hs.73793 NM_003376 VEGFA Vascular endothelial growth factor A

Hs.534255 NM_004048 B2M Beta-2-microglobulin

Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1

Hs.523185 NM_012423 RPL13A Ribosomal protein L13a

Hs.592355 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase

β-ΡΙΧ

Hs.520640 NM_001101 ACTB Actin, beta

N/A SA_00105 HGDC Human Genomic DNA Contamination

N/A SA_00104 RTC Reverse Transcription Control

N/A SA_00104 RTC Reverse Transcription Control

N/A SA_00104 RTC Reverse Transcription Control N/A SA_00103 PPC Positive PCR Control

N/A SA_00103 PPC Positive PCR Control

N/A SA_00103 PPC Positive PCR Control

4. Analysis of cell migration according to ?- £Y expression.

To determine whether β-PJX ls required for MSC migration, we prepared C- MSCs with β-ΡΙΧ knockdown by lentiviral-transduced sh IMA, and ALS-MSCs ectopically expressing β-ΡΙΧ. The knockdown model had reduced levels of β-ΡΙΧ mRNA and protein (Fig. 3a). ?-/¾ was over-expressed in ALS-MSCs transduced with lentiviral DNAs bearing the β-ΡΙΧ cDNAs PIX (Fig. 3b). The changes in β-ΡΙΧ expression levels did not affect the MSC surface marker CD45-CD34- CD29+CD73+CD105+CD44+HLA-DR-phenotype (Fig. 8). However, the ALS-MSCs with over-expressed β-ΡΙΧ had restored migratory capacity, whereas the β-ΡΙΧ knockdown C-MSCs had drastically reduced migratory capacity as determined by an in vitro transwell chemotaxis assay (Fig. 3c). These results establish β-PJX as a facilitator of MSC migration.

We next examined the in vivo migration of ALS-MSCs over-expressing β-ΡΙΧ and CMSCs with β-ΡΙΧ knockdown. These MSCs were implanted into rat brains subjected to ischemic stroke. T2*-weighted images of rat brains confirmed the in vitro finding that β-ΡΙΧ expression is necessary for MSC migration (Fig. 4a-4b). The β-ΡΙΧ knockdown CMSCs showed much lower levels of migration (2 out of 10) into the ischemic focus than CMSCs (8 of 10) (Fig. 4a). However, migration was enhanced by β-ΡΙΧ over-expression in ALS-MSCs (7 of 10) and detected on MRI in comparison to ALS-MSCs (1 of 10) (Fig. 4b).

5. Western blot and immunocellularchemical assay

We next determined whether β-ΡΙΧ mRNA and protein expression levels were correlated with the migratory activity of MSCs using RT-PCR, immunoblotting, and immunohistochemistry (Fig. 2). The expression levels of β-ΡΙΧ mRNA and protein were significantly higher in C-MSCs, UCB-MSCs, and hUC-MSCs than ALS-MSCs (Fig. 2b-2d). Thus decreased expression of β-PIXmRNA and protein was associated with decreased migratory capacity of MSCs.

6. Comparison of behavioral functions between /ENACT knockdowned and vehicle C-MSCs.

We next determined if the migration of the implanted MSCs into the lesion site improved motor function recovery for the ischemic stroke rats. The rats that received β-ΡΙΧ knockdown C-MSCs did not demonstrate any neurological function recovery, whereas rats that received C-MSCs transplant did show improvement (Fig. 9). Moreover, rats that received ?7¾¾Over-expressing ALS-MSCs did not improve neurological functions and was similar to ALS-MSCs transplant rats. These results suggested that the migration of the implanted MSCs was necessary, but insufficient, for the ability of MSC transplants to improve motor functions of ischemic stroke rats.

7. Comparison of neurotrophic factors.

We found that the levels of two neurotrophic factors, SDF-la and VEGF, were significantly lower for ALS-MSCs than for C-MSCs (Supplementary Fig. 6A, 6B). However, β-ΡΙΧ knockdown in C-MSCs or over-expression in ALS-MSCs did not affect SDF-la or VEGF expression levels (Fig. lOa-lOb). Thus, autologous ALS-MSC transplants would be expected to require both β-ΡΙΧ over-expression and supplementation of neurotrophic factors such as SDF-la and VEGF to restore stem cell migration toward lesion sites that is needed for the improvement of motor function.

References 1. Graziano, A. et al., Concave pit-containing scaffold surfaces improve stem cell derived osteoblast performance and lead to significant bone tissue formation. PLoS ONE 2 (6), e496 (2007).

2. Lambrechts, D. et al., VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (4), 383(2003).

3. Volinsky, N., Gantman, A., and Yablonski, D., A Pak- and Pix-dependent branch of the SDF-lalpha signalling pathway mediates T cell chemotaxis across restrictive barriers. Biochem J397 (1), 213 (2006).

4. ten Klooster, J. P., Jaffer, Z. M., Chernoff, J., and Hordijk, P. L, Targeting and activation of Racl are mediated by the exchange factor beta-Pix. J Cell Biol 172 (5), 759 (2006).

5. Shin, E. Y. et al., Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth. J Biol Chem 277(46), 44417(2002).

6. Mazzini, L. et al., Stem cell treatment in Amyotrophic Lateral Sclerosis. J Neurol Sci 265 (1-2), 78 (2008).

7. Kim, H.Y. et al., Efficacy and Safety of Autologous Bone Marrow-derived Mesenchymal Stem Cell Treatment in Patients with Amyotrophic Lateral Sclerosis. J

Korean Neurol Assoc 27 (2), 163 (2009).

8. Koh, S. H. et al., Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 1229, 233 (2008).

9. Omura, T. et al., Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stro e 37 (5), 1307 (2006).

10. Ko, I. K. et al., In vivo MR imaging of tissue-engineered human mesenchymal stem cells transplanted to mouse: a preliminary study. Ann Biomed Eng 35 (1), 101 (2007).

11. Arbab, A. S. et al., Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 104 (4), 1217(2004).

12. Koh, S. H. et al., Erythropoietin increases the motility of human bone marrow multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev {2009).

Claims

What is claimed is:

1. A composition for improving the migration potential of a stem cell, which comprises as an active ingredient a gene delivery system comprising a nucleotide sequence encoding β-ΡΙΧ having the amino acid sequence of SEQ ID NO:2.

2. The composition according to claim 1, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:l.

3. The composition according to claim 1, wherein the stem cell is a mesenchymal stem cell (MSC).

4. The composition according to claim 1, wherein the gene delivery system is a plasmid, a recombinant adenovirus, an adeno-associated virus (AAV), a retrovirus, a lentivirus, a herpesvirus, a vaccinia virus, a liposome or a niosome.

5. The composition according to claim 4, wherein the gene delivery system is the lentivirus.

6. A stem cell transformed with the composition according to any one of claims 1 to 5.

7. A composition for treating a neurological disease comprising the stem cell according to claim 6.

8. The composition according to claim 7, wherein the neurological disease is ischemic stroke.

9. A method for evaluating the migration potential of a stem cell, comprising measuring the expression level of the nucleotide sequence of SEQ ID NO:l in a biological sample.

10. A method for screening an adjuvant for cell therapy improving the migration potential of a stem cell to treat neurological diseases, comprising the steps of:

(a) contacting a test substance to a cell comprising the nucleotide sequence of SEQ ID NO:l; and

(b) measuring the expression level of the nucleotide sequence of SEQ ID NO:l, wherein when the expression level of the nucleotide sequence of SEQ ID NO: l is increased, the test substance is determined the adjuvant for cell therapy improving the migration potential of the stem cell to treat neurological diseases.

11. A method for improving the migration potential of a stem cell, comprising contacting to the stem cell a gene delivery system comprising a nucleotide sequence encoding β-ΡΙΧ having the amino acid sequence of SEQ ID NO: 2.

12. The method according to claim 11, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:l.

13. The method according to claim 11, wherein the stem cell is a mesenchymal stem cell (MSC).

14. The method according to claim 11, wherein the gene delivery system is a plasmid, a recombinant adenovirus, an adeno-associated virus (AAV), a retrovirus, a lentivirus, a herpesvirus, a vaccinia virus, a liposome or a niosome.

15. The method according to claim 4, wherein the gene delivery system is the lentivirus.

16. A method for treating a neurological disease in a subject in need of such treatment, comprising administering to the subject a stem cell pre-treated with a gene delivery system comprising a nucleotide sequence encoding β-ΡΙΧ having the amino acid sequence of SEQ ID NO:2.

17. The method according to claim 16, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: l.

18. The method according to claim 16, wherein the stem cell is a mesenchymal stem cell (MSC).

19. The method according to claim 16, wherein the gene delivery system is a plasmid, a recombinant adenovirus, an adeno-associated virus (AAV), a retrovirus, a lentivirus, a herpesvirus, a vaccinia virus, a liposome or a niosome.

20. The method according to claim 16, wherein the gene delivery system is the lentivirus.